Case number IPR2024-00631
Apotex Inc. et al. v. Novo Nordisk A/S > Documents
| Date Field | Doc. No. | Party | Description |
|---|---|---|---|
| Jun 12, 2024 | 14 | patent_owner | Patent Owner's Motion to Seal Download |
| Jun 12, 2024 | 2001 | patent_owner | EX2001 - Docket Sheet from PTACTS, Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724 Download |
| Jun 12, 2024 | 2002 | patent_owner | EX2002 - Joint Stipulation to Modify Due Dates 2, 3, 4, 5, 6, 7 and 8, Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724 Paper 47 Download |
| Jun 12, 2024 | 2003 | patent_owner | EX2003 - June 7, 2024 Joint Stipulation to Modify Due Dates 3, 4, 5, 6, 7 and 8, Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, Paper 56 Download |
| Jun 12, 2024 | 2004 | patent_owner | Download |
| Jun 12, 2024 | 2005 | patent_owner | EX2005 - Excerpted Declaration of George L. Bakris, M.D., Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, EX2011 Download |
| Jun 12, 2024 | 2006 | patent_owner | EX2006 - Excerpted Declaration of Robin S. Goland, M.D., Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, EX2054 Download |
| Jun 12, 2024 | 2007 | patent_owner | EX2007 - Excerpted Declaration of Michael J. Blaha, M.D., Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, EX2055 Download |
| Jun 12, 2024 | 2008 | patent_owner | EX2008 - Excerpted Declaration of Christopher A. Vellturo, Ph.D., Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, EX2300 Download |
| Jun 12, 2024 | 2009 | patent_owner | EX2009 - Excerpted Declaration of Patrick J. Sinko, Ph.D., Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, EX2056 Download |
| Jun 12, 2024 | 2010 | patent_owner | EX2010 - June 10, 2024 Email from Counsel for Petitioner re: IPR2024-00631 Download |
| Jun 12, 2024 | 2011 | patent_owner | EX2011 - Patent Exclusivity for N209637 (Semaglutide/Ozempic), Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, U.S. Food & Drug Administration Download |
| Jun 12, 2024 | 2012 | patent_owner | EX2012 - Declaration of Sayem Osman Download |
| Apr 15, 2024 | 11 | petitioner | Apotex's Motion to Seal Download |
| Apr 15, 2024 | 12 | petitioner | Redacted - Apotex's Reply to Patent Owner's Opposition to Petitioner's Motion for Joinder Download |
| Apr 15, 2024 | 13 | petitioner | Redacted - Patent Owner's Opposition to Petitioner's Motion for Joinder (Paper No. 9) Download |
| Apr 15, 2024 | 0 | petitioner | Apotex's Reply to Patent Owner's Opposition to Petitioner's Motion for Joinder Download |
| Apr 15, 2024 | 0 | petitioner | Apotex's Reply to Patent Owner's Opposition to Petitioner's Motion for JoinderION FOR JOINDE Download |
| Mar 12, 2024 | 8 | board | Notice: Notice filing date accorded Download |
| Mar 11, 2024 | 3001 | board | Exhibit 3001 Download |
| Mar 1, 2024 | 1 | petitioner | Petition : as filed Download |
| Mar 1, 2024 | 1001 | petitioner | 1001 U.S. Patent No. 10,335,462 Download |
| Mar 1, 2024 | 1002 | petitioner | 1002 Prosecution history excerpts for U.S. Patent No. 10,335,462 Download |
| Mar 1, 2024 | 1003 | petitioner | 1003 Bantle Declaration Download |
| Mar 1, 2024 | 1004 | petitioner | CV of John Bantle, MD Download |
| Mar 1, 2024 | 1005 | petitioner | 1005 Declaration of William J. Jusko, Ph.D. Download |
| Mar 1, 2024 | 1006 | petitioner | 1006 CV of William J. Jusko, Ph.D. Download |
| Mar 1, 2024 | 1007 | petitioner | 1007 Declaration of Paul Dalby, Ph.D. Download |
| Mar 1, 2024 | 1008 | petitioner | 1008 CV of Paul Dalby, Ph.D. Download |
| Mar 1, 2024 | 1011 | petitioner | 1011 WO 2011/138421 Download |
| Mar 1, 2024 | 1012 | petitioner | 1012 Lovshin, Incretin-Based Therapies for Type 2 Diabetes Mellitus, 5 NATU Download |
| Mar 1, 2024 | 1013 | petitioner | 1013 Clinical Trial No. NCT00696657 Download |
| Mar 1, 2024 | 1014 | petitioner | 1014 Clinical Trial No. NCT00851773 Download |
| Mar 1, 2024 | 1015 | petitioner | 1015 WO 2006/097537 Download |
| Mar 1, 2024 | 1016 | petitioner | 1016 U.S. Patent Application Pub. No. US2007/0010424 Download |
| Mar 1, 2024 | 1017 | petitioner | 1017 U.S. Patent No. 5,512,549 Download |
| Mar 1, 2024 | 1018 | petitioner | 1018 Banting, The Internal Secretion of the Pancreas, 7 J. LAB. CLINICAL ME Download |
| Mar 1, 2024 | 1019 | petitioner | 1019 Bell, Hamster Preproglucagon Contains the Sequence of Glucagon and Two Download |
| Mar 1, 2024 | 1020 | petitioner | 1020 Bydureon prescribing information (Jan. 2012) Download |
| Mar 1, 2024 | 1021 | petitioner | 1021 Byetta prescribing information (Oct. 2009) Download |
| Mar 1, 2024 | 1022 | petitioner | 1022 Drab, Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current S Download |
| Mar 1, 2024 | 1023 | petitioner | 1023 Drucker, Enhancing Incretin Action for the Treatment of Type 2 Diabete Download |
| Mar 1, 2024 | 1024 | petitioner | 1024 Drucker, The Incretin System: Glucagon-Like Peptide-1 Receptor Agonist Download |
| Mar 1, 2024 | 1025 | petitioner | 1025 Glaesner, Engineering and Characterization of the Long-Acting Glucagon Download |
| Mar 1, 2024 | 1026 | petitioner | Download |
| Mar 1, 2024 | 1027 | petitioner | 1027 Holst, Truncated Glucagon-like Peptide I, an Insulin-Releasing Hormone Download |
| Mar 1, 2024 | 1028 | petitioner | 1028 Holst, Glucagon-Like Peptide 1 and Inhibitors of Dipeptidyl Peptidase Download |
| Mar 1, 2024 | 1029 | petitioner | Download |
| Mar 1, 2024 | 1030 | petitioner | 1030 Kim, Effects of Once-Weekly Dosing of a Long-Acting Release Formulatio Download |
| Mar 1, 2024 | 1031 | petitioner | Download |
| Mar 1, 2024 | 1032 | petitioner | 1032 Knudsen, Glucagon-like Peptide-1: The Basis of a New Class of Treatmen Download |
| Mar 1, 2024 | 1033 | petitioner | Download |
| Mar 1, 2024 | 1034 | petitioner | 1034 U.S. Patent No. 6,268,343 Download |
| Mar 1, 2024 | 1035 | petitioner | Download |
| Mar 1, 2024 | 1036 | petitioner | 1036 Mojsov, Insulinotropin: Glucagon-like Peptide I (7-37) Co-encoded in t Download |
| Mar 1, 2024 | 1037 | petitioner | 1037 Nielsen, Pharmacology of Exenatide (Synthetic Exendin-4): A Potential Download |
| Mar 1, 2024 | 1038 | petitioner | 1038 Seino, Dose-Dependent Improvement in Glycemia with Once-Daily Liraglut Download |
| Mar 1, 2024 | 1039 | petitioner | Download |
| Mar 1, 2024 | 1040 | petitioner | Download |
| Mar 1, 2024 | 1041 | petitioner | 1041 WO 03/002136 Download |
| Mar 1, 2024 | 1042 | petitioner | 1042 WO 91/11457 Download |
| Mar 1, 2024 | 1043 | petitioner | 1043 U.S. Patent App. Pub. 2004/0102486 Download |
| Mar 1, 2024 | 1044 | petitioner | Download |
| Mar 1, 2024 | 1045 | petitioner | 1045 Shargel, APPLIED BIOPHARMACEUTICS & PHARMACOKINETICS (5th ed. 2005) Download |
| Mar 1, 2024 | 1046 | petitioner | 1046 Yun, Pharmacokinetic and Pharmacodynamic Modelling of the Effects of G Download |
| Mar 1, 2024 | 1047 | petitioner | 1047 Tamimi, Drug Development: From Concept to Marketing!, 113 NEPHRON CLIN Download |
| Mar 1, 2024 | 1048 | petitioner | 1048 FDA Guidance for Industry, Exposure-Response Relationships -Study Desi Download |
| Mar 1, 2024 | 1049 | petitioner | 1049 International Conference on Harmonisation; Dose-Response Information t Download |
| Mar 1, 2024 | 1050 | petitioner | 1050 Garber, Efficacy of Metformin in Type II Diabetes: Results of a Double Download |
| Mar 1, 2024 | 1051 | petitioner | 1051 Landersdorfer, Pharmacokinetic/Pharmacodynamic Modelling in Diabetes M Download |
| Mar 1, 2024 | 1052 | petitioner | 1052 Madsbad, An Overview of Once-Weekly Glucagon-Like Peptide-1 Receptor A Download |
| Mar 1, 2024 | 1053 | petitioner | Download |
| Mar 1, 2024 | 1054 | petitioner | 1054 Landersdorfer, Mechanism-Based Population Pharmacokinetic Modelling in Download |
| Mar 1, 2024 | 1055 | petitioner | 1055 Landersdorfer, Mechanism-Based Population Modelling of the Effects of Download |
| Mar 1, 2024 | 1056 | petitioner | 1056 U.S. Patent No. 5,118,666 Download |
| Mar 1, 2024 | 1057 | petitioner | 1057 WO 2011/073328 Download |
| Mar 1, 2024 | 1058 | petitioner | 1058 Blonde, Comparison of Liraglutide Versus Other Incretin-Related Anti-H Download |
| Mar 1, 2024 | 1059 | petitioner | 1059 Murphy, Review of the Safety and Efficacy of Exenatide Once Weekly for Download |
| Mar 1, 2024 | 1060 | petitioner | 1060 WO 2011/058193 Download |
| Mar 1, 2024 | 1061 | petitioner | 1061 U.S. Patent App. Pub. No. 2011/0166321 Download |
| Mar 1, 2024 | 1062 | petitioner | Download |
| Mar 1, 2024 | 1063 | petitioner | 1063 Kirillova, Results and Outcome Reporting in ClinicalTrials.gov, What M Download |
| Mar 1, 2024 | 1064 | petitioner | 1064 Monami, Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body W Download |
| Mar 1, 2024 | 1065 | petitioner | 1065 Tasneem, The Database for Aggregate Analysis of ClinicalTrials.gov (AA Download |
| Mar 1, 2024 | 1066 | petitioner | 1066 Knudsen, Liraglutide: The Therapeutic Promise from Animal Models, 64(s Download |
| Mar 1, 2024 | 1067 | petitioner | 1067 U.S. Patent No. 8,536,122 Download |
| Mar 1, 2024 | 1068 | petitioner | 1068 U.S. Patent No. 8,129,343 Download |
| Mar 1, 2024 | 1069 | petitioner | 1069 REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (Alfonso R. Gennaro ed Download |
| Mar 1, 2024 | 1070 | petitioner | 1070 Boylan, Parenteral Products, in MODERN PHARMACEUTICS (Gilbert S. Banke Download |
| Mar 1, 2024 | 1071 | petitioner | 1071 U.S. Patent No. 6,284,727 Download |
| Mar 1, 2024 | 1072 | petitioner | 1072 U.S. Patent No. 5,164,366 Download |
| Mar 1, 2024 | 1073 | petitioner | 1073 U.S. Patent No. 6,458,924 Download |
| Mar 1, 2024 | 1074 | petitioner | 1074 WO 00/37098 Download |
| Mar 1, 2024 | 1075 | petitioner | 1075 U.S. Patent No. 7,022,674 Download |
| Mar 1, 2024 | 1076 | petitioner | 1076 ClinicalTrials.gov Background, CLINICALTRIALS.GOV, https://clinicaltri Download |
| Mar 1, 2024 | 1077 | petitioner | 1077 Award: ClinicalTrials.gov, https://ash.harvard.edu/news/clinicaltrials Download |
| Mar 1, 2024 | 1078 | petitioner | 1078 U.S. Patent App. Pub. No. 2004/0102486 Download |
| Mar 1, 2024 | 1079 | petitioner | 1079 NCT00167115, CLINICALTRIALS.GOV, https://www.clinicaltrials.gov/ct2/sh Download |
| Mar 1, 2024 | 1080 | petitioner | 1080 NCT01933490, CLINICALTRIALS.GOV, https://www.clinicaltrials.gov/ct2/sh Download |
| Mar 1, 2024 | 1081 | petitioner | 1081 Ozempic prescribing information (Oct. 2022) Download |
| Mar 1, 2024 | 1082 | petitioner | 1082 Scheduling Order, Novo Nordisk Inc. v. Rio Biopharmaceuticals Inc., No Download |
| Mar 1, 2024 | 1083 | petitioner | 1083 Transfer Order, In re: Ozempic (Semaglutide) Patent Litigation, No. 30 Download |
| Mar 1, 2024 | 1084 | petitioner | 1084 EMA, ICH Topic S 7 A Safety Pharmacology Studies for Human Pharmaceuti Download |
| Mar 1, 2024 | 1085 | petitioner | 1085 ACS Publications, https://pubs.acs.org/toc/jmcmar/47/17; https://pubs. Download |
| Mar 1, 2024 | 1086 | petitioner | Download |
| Mar 1, 2024 | 1087 | petitioner | 1087 Prosecution history excerpts for U.S. Patent No. 9,764,003 Download |
| Mar 1, 2024 | 1501 | petitioner | 1501 Declaration of Judith Korner, M.D., Ph.D. Download |
| Mar 1, 2024 | 1502 | petitioner | 1502 CV of Judith Korner, M.D., Ph.D. Download |
| Mar 1, 2024 | 1503 | petitioner | 1503 Declaration of Mark J. Ratain, M.D. Download |
| Mar 1, 2024 | 1504 | petitioner | 1504 CV of Mark J. Ratain, M.D. Download |
| Mar 1, 2024 | 1505 | petitioner | 1505 Declaration of Hugh DC Smyth, Ph.D. Download |
| Mar 1, 2024 | 1506 | petitioner | 1506 CV of Hugh DC Smyth, Ph.D. Download |
| Mar 1, 2024 | 2 | petitioner | Notice : Power of Attorney Download |
| Mar 1, 2024 | 3 | petitioner | Motion to Seal and Enter Protective Order Download |
| Mar 1, 2024 | 4 | petitioner | Motion for Joinder (redacted) Download |
